2197.HK Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (29 apr 2024 @ 09:06):

Stats
Dagens volum	695 500
Gjennomsnittsvolum	1.29M
Markedsverdi	453.95M
EPS	HKD0 ( 2024-03-25 )
Neste inntjeningsdato	( HKD0 ) 2024-05-29
Last Dividend	HKD0 ( N/A )
Next Dividend	HKD0 ( N/A )
P/E	-2.92
ATR14	HKD0.00300 (0.86%)

Volum Korrelasjon

Lang: -0.19 (neutral)

Kort: -0.13 (neutral)

Signal:(39.933) Neutral

Clover Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Clover Korrelasjon - Valuta/Råvare

0.48
( neutral )

0.62
( weak )

0.00
( neutral )

-0.17
( neutral )

Clover Økonomi

Annual	2023
Omsetning:	HKD39.26M
Bruttogevinst:	HKD-1.67B (-4 262.30 %)
EPS:	HKD-0.110

FY	2023
Omsetning:	HKD39.26M
Bruttogevinst:	HKD-1.67B (-4 262.30 %)
EPS:	HKD-0.110

FY	2022
Omsetning:	HKD0
Bruttogevinst:	HKD-475.64M (0.00 %)
EPS:	HKD-2.22

FY	2021
Omsetning:	HKD0.00
Bruttogevinst:	HKD0.00 (0.00 %)
EPS:	HKD-5.19

Financial Reports:

No articles found.

Clover

Clover Biopharmaceuticals, Ltd., a biotechnology company, engages in the research, development, and commercialization of novel vaccines and biologic therapeutic candidates for infectious diseases, and cancer and autoimmune diseases. It is developing SCB-2019 (CpG 1018/Alum), a COVID-19 vaccine candidate that is in Phase II/III clinical trial; SCB-313, a trimeric fusion protein for the treatment of malignant ascites, malignant pleural effusions, and peritoneal carcinomatosis to address the global unmet medical need of intracavitary malignancies; SCB-808 that is in pivotal Phase III clinical trial for the treatment of rheumatic diseases; SCB-420, an aflibercept biosimilar that is in pre-clinical development for ophthalmologic diseases, such as wet age-related macular degeneration; and SCB-219, a novel TPOR agonist that is in pre-clinical development for the treatment of chemotherapy-induced thrombocytopenia and immune thrombocytopenic purpura. The company has a collaboration and supply arrangement with Dynavax to supply its CpG 1018 adjuvant for pre-clinical studies. Clover Biopharmaceuticals, Ltd. was founded in 2007 and is headquartered in Shanghai, China.